Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Hanna L. M. Koskela, Mohamed El Missiry, Anniina Ruusila, Perttu Koskenvesa, Tim H. Bruemmendorf, Bjorn T. Gjertsen, Jeroen Janssen, Kourosh Lotfi, Berit Markevarn, Ulla Olsson-Stromberg, Leif Stenke, Jesper Stentoft, Johan Richter, Henrik Hjorth-Hansen, Anna Kreutzman, Satu Mustjoki

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalJournal of Cancer Research and Clinical Oncology
Volume143
Issue number8
Pages (from-to)1543-1554
Number of pages12
ISSN0171-5216
DOIs
Publication statusPublished - Aug 2017
MoE publication typeA1 Journal article-refereed

Fields of Science

  • CML
  • Tyrosine kinase inhibitor
  • B cell
  • Immunoglobulin
  • PATIENTS RECEIVING IMATINIB
  • CHRONIC-PHASE
  • PHILADELPHIA-CHROMOSOME
  • BONE-MARROW
  • FOLLOW-UP
  • DASATINIB
  • NILOTINIB
  • ANTIGEN
  • HYPOGAMMAGLOBULINEMIA
  • COMBINATION
  • 3122 Cancers

Cite this

Koskela, Hanna L. M. ; El Missiry, Mohamed ; Ruusila, Anniina ; Koskenvesa, Perttu ; Bruemmendorf, Tim H. ; Gjertsen, Bjorn T. ; Janssen, Jeroen ; Lotfi, Kourosh ; Markevarn, Berit ; Olsson-Stromberg, Ulla ; Stenke, Leif ; Stentoft, Jesper ; Richter, Johan ; Hjorth-Hansen, Henrik ; Kreutzman, Anna ; Mustjoki, Satu. / Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. In: Journal of Cancer Research and Clinical Oncology. 2017 ; Vol. 143, No. 8. pp. 1543-1554.
@article{83340c96ff3f4366a8b9cc9cfd47d5b7,
title = "Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia",
keywords = "CML, Tyrosine kinase inhibitor, B cell, Immunoglobulin, PATIENTS RECEIVING IMATINIB, CHRONIC-PHASE, PHILADELPHIA-CHROMOSOME, BONE-MARROW, FOLLOW-UP, DASATINIB, NILOTINIB, ANTIGEN, HYPOGAMMAGLOBULINEMIA, COMBINATION, 3122 Cancers",
author = "Koskela, {Hanna L. M.} and {El Missiry}, Mohamed and Anniina Ruusila and Perttu Koskenvesa and Bruemmendorf, {Tim H.} and Gjertsen, {Bjorn T.} and Jeroen Janssen and Kourosh Lotfi and Berit Markevarn and Ulla Olsson-Stromberg and Leif Stenke and Jesper Stentoft and Johan Richter and Henrik Hjorth-Hansen and Anna Kreutzman and Satu Mustjoki",
year = "2017",
month = "8",
doi = "10.1007/s00432-017-2378-6",
language = "English",
volume = "143",
pages = "1543--1554",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer",
number = "8",

}

Koskela, HLM, El Missiry, M, Ruusila, A, Koskenvesa, P, Bruemmendorf, TH, Gjertsen, BT, Janssen, J, Lotfi, K, Markevarn, B, Olsson-Stromberg, U, Stenke, L, Stentoft, J, Richter, J, Hjorth-Hansen, H, Kreutzman, A & Mustjoki, S 2017, 'Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia' Journal of Cancer Research and Clinical Oncology, vol. 143, no. 8, pp. 1543-1554. https://doi.org/10.1007/s00432-017-2378-6

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. / Koskela, Hanna L. M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Bruemmendorf, Tim H.; Gjertsen, Bjorn T.; Janssen, Jeroen; Lotfi, Kourosh; Markevarn, Berit; Olsson-Stromberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu.

In: Journal of Cancer Research and Clinical Oncology, Vol. 143, No. 8, 08.2017, p. 1543-1554.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

AU - Koskela, Hanna L. M.

AU - El Missiry, Mohamed

AU - Ruusila, Anniina

AU - Koskenvesa, Perttu

AU - Bruemmendorf, Tim H.

AU - Gjertsen, Bjorn T.

AU - Janssen, Jeroen

AU - Lotfi, Kourosh

AU - Markevarn, Berit

AU - Olsson-Stromberg, Ulla

AU - Stenke, Leif

AU - Stentoft, Jesper

AU - Richter, Johan

AU - Hjorth-Hansen, Henrik

AU - Kreutzman, Anna

AU - Mustjoki, Satu

PY - 2017/8

Y1 - 2017/8

KW - CML

KW - Tyrosine kinase inhibitor

KW - B cell

KW - Immunoglobulin

KW - PATIENTS RECEIVING IMATINIB

KW - CHRONIC-PHASE

KW - PHILADELPHIA-CHROMOSOME

KW - BONE-MARROW

KW - FOLLOW-UP

KW - DASATINIB

KW - NILOTINIB

KW - ANTIGEN

KW - HYPOGAMMAGLOBULINEMIA

KW - COMBINATION

KW - 3122 Cancers

U2 - 10.1007/s00432-017-2378-6

DO - 10.1007/s00432-017-2378-6

M3 - Article

VL - 143

SP - 1543

EP - 1554

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 8

ER -